<DOC>
	<DOCNO>NCT02122263</DOCNO>
	<brief_summary>To evaluate effect Bariatric surgery extent liver fat liver fibrosis different metabolic parameter patient undergo sleeve gastrectomy surgery .</brief_summary>
	<brief_title>Transient Elastography Liver ( Fibroscan ) Bariatric Surgery</brief_title>
	<detailed_description>The effect bariatric surgery extent fat extent liver fibrosis follow sleeve gastrtrectomy unknown . Methods : 60 obese NAFLD patient undergo sleeve gastrectomy surgery . Measurements conduct : baseline , 6 Month include : abdominal US , Fibroscan elastography , biochemical test , anthropometric measurement , questionnaire demographic detail , quality life , food intake , food tolerance habitual physical activity . Primary Outcome Measures : Liver fat quantification ( control attenuation parameter ; CAP ) stiffness baseline 6 month fibroscan . The liver stiffness measure Fibroscan volume approximate 1 cm wide 4 cm long cylinder , represent 1/500 liver tissue ( 100 time great biopsy sample ) . The result Fibroscan express KiloPascals ( kPa ) . The Fibroscan XL probe reduces Fibroscan failure facilitate reliable liver stiffness measurement obese patient compare common M probe . Secondary Outcome Measures : metabolic parameter include insuline resistance , CRP , MDA , Paraoxonase , bile acid level . Quality life Food tolerance bariatric surgery</detailed_description>
	<criteria>Subjects 1865 year old BMI &gt; 40 kg/m² BMI &gt; 35 kg/m² comorbidities Willingness take metformin day 6 month Ultrasound diagnosed NAFLD patient Reading speak Hebrew Subject mental illness cognitive deterioration Use probiotic/antibiotic 3 mount surgery Use antibiotic 1 week study Drug addiction Excessive alcohol consumption ( ≥ 30 g/day men ≥ 20 g/day woman ) Treatment drug know cause hepatic steatosis elevation liver enzyme ( e.g . Corticosteroids , HAART , Amiodarone , high dose estrogen ) Treatment drug supplement may improve hepatic steatosis liver enzyme ( Vitamin E , Milk thistle , ω3 fatty acid , Ursodeoxycholic acid ) 3 month prior initiation study Other cause chronic liver disease ( e.g . viral hepatitis : HBV/HCV + , autoimmune hepatitis , Hemochromatosis , Wilson 's disease ) Diabetic patient treat antidiabetic medication , except diabetic patient treat least 6 month exclusively Metformin stable dose Subjects begin new lipid reduction medication less 6 month prior initiation study Subjects chronic condition could interfere study : active cancer , organ transplant subject , advance kidney liver disease , inflammatory bowel disease systemic inflammatory condition Bariatric surgery past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>